

//
//
//

()

*

Archive of SID

$5-7 \times 10 \text{ L/m}^2$

CCI

$10 \times 10 \text{ L/m}^2$

HLA

()

(.)

HLA

* /L

(%) HLA

%

(%) %

* /L

()

*

%

×(_____) = CCI

10¹¹ ×

HLA-DR

* /L

CCI

* /L

HLA

%

(.)

Archive of SID

HLA

Archive of SID

()	()	
/	/	() •
()	(%)	•
(/)	(/)	%
(/)	()	ALL •
(/)	(%)	AML •
(/)	()	•
(/)	()	•
/ ± /	/ ± /	•
/ ± /	/ ± /	•
		•
/		•
	/	•

CCI

%

P < /

(%) (P < / P < /)
(% /)

()

%

%

.()

% /

%

()

% /

REFERENCES

2. Barz D, Staack D, Lehmann R, Stange K, Schnurstein K. Antibody formation after filtered blood cell replacement in hematologic-oncologic patients. *Beitr Infusionsther Transfusionsmed* 1996; 33: 30-4.
3. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. *Transfusion* 1993; 33(8): 665-70.
4. Hoffman R. *Hematology: Basic principles and practice*. USA: Churchill Livingstone, 1991.
5. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. *Blood* 1988; 71(5): 1402-7.